Finance entity
Iovance Biotherapeutics is most often covered alongside Amtagvi, which appears in 1 of these 2 stories. At 5, the average consequence score sits below the same-window beat average of 6. Source depth averages 3 original sources per story, versus 2.6 across the same-window beat baseline.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Iovance Biotherapeutics is most often covered alongside Amtagvi, which appears in 1 of these 2 stories. At 5, the average consequence score sits below the same-window beat average of 6. Source depth averages 3 original sources per story, versus 2.6 across the same-window beat baseline. The clearest coverage concentration is earnings: 1 of 2 stories, with the rest divided among 1 other category. This profile follows 2 Finance stories mentioning Iovance Biotherapeutics across the period from February 23, 2026 to February 26, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 358 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Iovance Biotherapeutics. Shared-story counts are live from our verified record — not editorial picks.
MarketBeat's latest stock screeners identify a diverse range of opportunities across fitness, fintech, and value sectors as investors recalibrate for late Q1. From the resurgence of brick-and-mortar gyms to the defensive positioning of banking giants, these picks reflect a market balancing growth and risk.
Source: Watch List News · Watch List News
Iovance Biotherapeutics and Fidelity National Financial are preparing to report Q4 2025 results, with investors focusing on the commercial scaling of cell therapies and the resilience of the title insurance market. These reports will provide critical data on biotech commercialization and the health of the U.S. housing sector.
Iovance Biotherapeutics is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
